Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
By Elana Gotkine HealthDay Reporter
TUESDAY, July 22, 2025 -- For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other antidiabetic drugs, according to a study published online July 15 in JAMA Network Open.
Huan-Tang Lin, M.D., Ph.D., from Chang Gung Memorial Hospital at Linkou in Taiwan, and colleagues examined the association of semaglutide and tirzepatide with the incidence of dementia, Parkinson disease, ischemic stroke, intracerebral hemorrhage, and all-cause mortality compared to other antidiabetic drugs in a retrospective cohort study analyzing electronic health record-based data for adults aged 40 years or older with type 2 diabetes and obesity.
The study included 60,860 adults with type 2 diabetes and obesity: 30,430 in the GLP-1 RA group and 30,430 in the other antidiabetic drug group (biguanides, sulfonylureas, dipeptidyl peptidase 4 inhibitors, sodium-glucose cotransporter 2 inhibitors, thiazolidinediones, and α-glucosidase inhibitors) after propensity score matching. The researchers found that GLP-1 RA users had a lower risk for dementia, ischemic stroke, and all-cause mortality during a seven-year follow-up (hazard ratios, 0.63, 0.81, and 0.70, respectively), while no significant differences were seen in the risks for Parkinson disease or intracerebral hemorrhage. Greater benefits were seen for those aged 60 years or older, women, and patients with a body mass index of 30 to 40 kg/m2.
"These findings highlight the possible role of GLP-1 RAs in mitigating neurodegenerative and cerebrovascular risks in this high-risk population," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
GLP-1 Receptor Agonists Linked to Reduced Risk for Developing Uveitis
TUESDAY, Sept. 2, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduction in the risk for developing uveitis, according to a study published...
Type of Hormone Therapy Used After Menopause Affects Memory Performance
FRIDAY, Aug. 29, 2025 -- Earlier age at menopause is associated with lower scores on all cognitive domains, and menopausal hormone therapy (MHT) differentially affects cognition...
Mediterranean Diet Beneficial in Those With High Alzheimer Disease Risk
THURSDAY, Aug. 28, 2025 -- Individuals at high genetic risk for Alzheimer disease (AD) and AD-related dementias (ADRDs) derive benefit from a Mediterranean diet, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.